指南与共识毛发、甲与色素性疾病

斑秃严重度与疾病负担指数(ASAMI)研究:全球专家共识确定严重度决定因素

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.
指南 / 共识 · JAMA Dermatol · 2024-01-01

该研究采用eDelphi方法,邀请全球74名毛发与头皮疾病专家,经3轮调查(64人完成首轮、58人完成第二轮、42人参与最终视频会议),就斑秃严重度相关因素达成共识。107个问题中96个达成共识,识别出除头皮脱发外多个可能加重病情的因素,并认为斑秃研究者全球评估量表能充分分类头皮脱发严重度。

要点

  • 斑秃严重度评估需兼顾脱发以外的因素,如病程≥12个月、复发≥3次、治疗反应不佳等。
  • 面部毛发受累、甲受累、生活质量受损及焦虑抑郁自杀意念史均与病情加重相关。
  • 专家共识认为斑秃研究者全球评估量表可充分分类头皮脱发严重度。

核心结论

  • 全球专家共识识别出斑秃严重度的多个决定因素,不仅包括头皮脱发,还涵盖其他结局指标。

研究设计与样本

  • eDelphi项目,邀请74名毛发与头皮疾病专家,进行3轮调查(前2轮文本网络应用,最终轮视频会议于2022年4月30日举行)。

主要发现

  • 64名专家完成首轮调查,58名完成第二轮,42名参与最终视频会议。
  • 107个问题中96个达成共识。
  • 识别出独立于斑秃严重度工具评分的因素:病程≥12个月、复发≥3次、局部或系统治疗反应不足、疾病快速进展、脱发难以遮盖、面部毛发受累(眉毛、睫毛和/或胡须)、甲受累、生活质量受损、因斑秃导致或加重的焦虑、抑郁或自杀意念史。
  • 共识认为斑秃研究者全球评估量表能充分分类头皮脱发严重度。

关键数值与推荐

  • 共识达成:107个问题中96个达成共识。
  • 严重度决定因素:病程≥12个月、复发≥3次、治疗反应不足、疾病快速进展、脱发难以遮盖、面部毛发受累、甲受累、生活质量受损、焦虑/抑郁/自杀意念史。
  • 斑秃研究者全球评估量表被共识认为可充分分类头皮脱发严重度。

临床怎么用

  • 临床评估斑秃严重度时,除头皮脱发外,应关注病程、复发次数、治疗反应、疾病进展速度、面部毛发及甲受累、生活质量及心理共病。
  • 可考虑使用斑秃研究者全球评估量表分类头皮脱发严重度。
  • 这些因素有助于识别适合当前及新兴系统治疗的候选患者。

局限性

  • 未来研究需纳入患者和公众视角,以对本项目识别的严重度相关领域进行权重赋值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. OBJECTIVE: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). EVIDENCE REVIEW: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022. FINDINGS: Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. CONCLUSIONS AND RELEVANCE: This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Moussa A, Bennett M, Wall D, et al. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity. JAMA Dermatol. 2024. PMID: 38324292. doi:10.1001/jamadermatol.2023.5869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。